Department of Pharmacology, New York Medical College, Valhalla, New York 10595, USA.
Am J Physiol Heart Circ Physiol. 2011 Mar;300(3):H1125-32. doi: 10.1152/ajpheart.00768.2010. Epub 2011 Jan 14.
Cyclooxygenase (COX)-2 expression is increased in the kidney of rats made diabetic with streptozotocin and associated with enhanced release of prostaglandins stimulated by arachidonic acid (AA). Treatment of diabetic rats with nitro-L-arginine methyl ester (L-NAME) to inhibit nitric oxide synthase or with tempol to reduce superoxide prevented these changes, suggesting the possibility that peroxynitrite (ONOO) may be the stimulus for the induction of renal COX-2 in diabetes. Consequently, we tested the effects of an ONOO decomposition catalyst, 5,10,15,20-tetrakis(N-methyl-4'-pyridyl)porphyrinato iron(III) (FeTMPyP), which was administered for 3-4 wk after the induction of diabetes. FeTMPyP treatment normalized the twofold increase in the expression of nitrotyrosine, a marker for ONOO formation, in the diabetic rat and prevented the increase in renal COX-2 expression without modifying the two- to threefold increases in renal release of prostaglandins PGE(2) and 6-ketoPGF(1α) in response to AA. FeTMPyP treatment of diabetic rats reduced the elevated creatinine clearance and urinary excretion of TNF-α and transforming growth factor (TGF)-β, suggesting a renoprotective effect. Double immunostaining of renal sections and immunoprecipitation of COX-2 and nitrotyrosine suggested nitration of COX-2 in diabetic rats. In cultured human umbilical vein endothelial cells (HUVECs) exposed to elevated glucose (450 mg/dl) or ONOO derived from 3-morpholinosydnonimine (SIN-1), expression of COX-2 was increased and was prevented when endothelial cells were treated with FeTMPyP. These results indicate that elevated glucose increases the formation of ONOO, which contributes to the induction of renal COX-2 in the diabetic rat.
环氧化酶 (COX)-2 在链脲佐菌素诱导的糖尿病大鼠肾脏中表达增加,并与花生四烯酸 (AA) 刺激的前列腺素释放增强有关。用硝基-L-精氨酸甲酯 (L-NAME) 抑制一氧化氮合酶或用 Tempo 减少超氧化物来治疗糖尿病大鼠,可防止这些变化,这表明过氧亚硝酸盐 (ONOO) 可能是诱导糖尿病肾 COX-2 的刺激物。因此,我们测试了 ONOO 分解催化剂 5,10,15,20-四(N-甲基-4'-吡啶基)卟啉铁(III)(FeTMPyP)的作用,该催化剂在糖尿病诱导后 3-4 周内给药。FeTMPyP 治疗使糖尿病大鼠中硝基酪氨酸(ONOO 形成的标志物)表达增加两倍恢复正常,并防止肾 COX-2 表达增加,而不改变 AA 反应时肾前列腺素 PGE(2)和 6-酮 PGF(1α)的两倍至三倍增加。FeTMPyP 治疗糖尿病大鼠可降低肌酐清除率和 TNF-α 和转化生长因子 (TGF)-β 的尿排泄增加,表明具有肾保护作用。肾切片的双重免疫染色和 COX-2 和硝基酪氨酸的免疫沉淀表明糖尿病大鼠 COX-2 的硝化。在暴露于高葡萄糖(450mg/dl)或 3-吗啉代-sydnonimine(SIN-1)衍生的 ONOO 的培养人脐静脉内皮细胞 (HUVEC) 中,COX-2 的表达增加,当内皮细胞用 FeTMPyP 处理时,表达增加被阻止。这些结果表明,高葡萄糖增加了 ONOO 的形成,这有助于诱导糖尿病大鼠肾 COX-2 的表达。